RXi Pharmaceuticals Corporation, an RNA-targeted technologies company, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period. This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each. Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side.
Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days.
Multiple dermal injections were well tolerated at all doses and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.
Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study. These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Why I’ll Talk Policy With Climate Change Deniers But Not Science
- Today's Global Warming Is Nothing Special
- HIP 116454b Shows That Despite Malfunction, Kepler Can Still Find Planets
- Worldwide, Life Expectancy Has Gone Up Over 6 Years Since 1990
- There Was No 'Paleo Diet' - Ancient People Ate What They Had
- Curiosity Detects Spike In Methane, And Other Organic Molecules, On Mars
- Time To Stop Thinking Of Video Games As Just 'Software'
- "You spend a great deal of time on the ideological motivations of climate change deniers, but mistakenly..."
- "Or we can blame my mother. It was to be their senior trip in 1959 but Castro and Che Guevara got..."
- "Solution aversion is very real. Talking about solutions which the climate skeptics could live with..."
- "For the avoidance of doubt, as judges are wont to say, it was Buckminster Fuller himself who first..."
- "Thank you for including the Four Myths of Nature. It is very helpful to keep these in mind when..."
- Tooth loss linked to slowing mind and body
- Latest evidence on using hormone replacement therapy for treating menopausal symptoms
- Less than half of UK prescriptions for antipsychotics issued for main licensed conditions
- Don't be tempted to buy your teen a cheap (old) car, parents warned
- The Lancet: Doctor who survived Ebola received experimental drug treatment